Supplemental material
Journal of Medical Economics
Volume 26, 2023 - Issue 1
Respiratory Medicine
Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants
Barry S. Rodgers-Graya Violicom Medical Limited, Aldermaston, UKCorrespondence[email protected]
https://orcid.org/0000-0003-0954-5587
https://orcid.org/0000-0003-0954-5587, John R. Fullartona Violicom Medical Limited, Aldermaston, UKhttps://orcid.org/0000-0001-9429-5994
https://orcid.org/0000-0001-9429-5994, Xavier Carbonell-Estranyb Neonatology Service, Hospital Clinic, Barcelona, Spainhttps://orcid.org/0000-0002-4453-3891
https://orcid.org/0000-0002-4453-3891, Ian P. Kearya Violicom Medical Limited, Aldermaston, UKhttps://orcid.org/0000-0003-0311-3177
https://orcid.org/0000-0003-0311-3177, Jean-Éric Tarridec Department of Health Research Methods, Evidence, and Impact (HEI), McMaster University, Hamilton, Canadahttps://orcid.org/0000-0003-2913-7580
https://orcid.org/0000-0003-2913-7580 & Bosco A. Paesd Department of Pediatrics (Neonatal Division), McMaster University, Hamilton, Canadahttps://orcid.org/0000-0002-3308-2706
https://orcid.org/0000-0002-3308-2706